Valerio Therapeutics Advances VIO-01 Clinical Trial with Positive Results

Paris, May 22, 2024 - Valerio Therapeutics S.A. has reported progress in its Phase 1/2 VIO-01 clinical trial. The first dose level, involving three patients, showed no significant adverse events. The Clinical Review Committee (CRC) cleared this phase, allowing the study to progress to the second dose cohort.

VIO-01 is a pan-DDR decoy designed to treat solid tumors. It’s developed from Valerio’s PlatON platform, enhanced for stability and tumor targeting. This treatment affects multiple DNA damage pathways, offering a wide range of applications beyond specific genetic mutations.

The CRC, including medical and safety teams, reviewed data from the first cohort with positive safety results. This trial aims to establish the recommended Phase 2 dose for various solid tumors.

Dr. Shefali Agarwal, CEO, highlighted this milestone as crucial in advancing VIO-01 and the PlatON platform. She acknowledged the dedication of the investigators and patients participating in the trial.